AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25565165 — intervention group
Group type: EXPERIMENTAL
Intervention: Autograft
Number of subjects: 30
Study 25565165 — intervention group
Group type: COMPARATOR
Intervention: Allograft
Number of subjects: 30
Study 24026598 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone + Pentoxifylline (40 mg prednisolone once a day and 400 mg pentoxifylline 3 times a day for 28 days)
Number of subjects: 270
Study 24026598 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone + Placebo (40 mg prednisolone and matching placebo for 28 days)
Number of subjects: 270
Study 24026598 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone + Pentoxifylline
Number of subjects: 270
Study 24026598 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone + Placebo
Number of subjects: 270
Study 20860784 — intervention group
Group type: EXPERIMENTAL
Intervention: Attempted vaginal birth
Number of subjects: 742
Study 20860784 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective caesarean section
Number of subjects: 742
Study 20860784 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual analogue scale ratings
Number of subjects: 742
Study 19643661 — intervention group
Group type: EXPERIMENTAL
Intervention: Short message service (SMS) intervention via cellular phone and Internet for 8 weeks
Number of subjects: 49
Study 19643661 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 49
Study 17365744 — intervention group
Group type: EXPERIMENTAL
Intervention: Fagerström Test for Nicotine Dependence (FTND) responses by African American adolescents
Number of subjects: 1139
Study 17365744 — intervention group
Group type: COMPARATOR
Intervention: Fagerström Test for Nicotine Dependence (FTND) responses by White adolescents
Number of subjects: 1139
Study 17365744 — intervention group
Group type: EXPERIMENTAL
Intervention: MIMIC modeling
Number of subjects: 1139
Study 15164108 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet A (8.4% SFA of TEI)
Number of subjects: 25
Study 15164108 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet B (11% SFA of TEI)
Number of subjects: 25
Study 11228275 — intervention group
Group type: EXPERIMENTAL
Intervention: Org31540/SR90107A 0.75 mg
Number of subjects: 933
Study 11228275 — intervention group
Group type: EXPERIMENTAL
Intervention: Org31540/SR90107A 1.5 mg
Number of subjects: 933
Study 11228275 — intervention group
Group type: EXPERIMENTAL
Intervention: Org31540/SR90107A 3.0 mg
Number of subjects: 933
Study 11228275 — intervention group
Group type: EXPERIMENTAL
Intervention: Org31540/SR90107A 6.0 mg
Number of subjects: 933
Study 11228275 — intervention group
Group type: EXPERIMENTAL
Intervention: Org31540/SR90107A 8.0 mg
Number of subjects: 933
Study 11228275 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin 30 mg every 12 hours
Number of subjects: 933
Study 9730093 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve and tendon gliding exercises
Number of subjects: 197
Study 9730093 — intervention group
Group type: COMPARATOR
Intervention: Standard conservative methods (Control)
Number of subjects: 197
Study 7815836 — intervention group
Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (ATRA) followed by intensive chemotherapy
Number of subjects: 0
Study 7815836 — intervention group
Group type: COMPARATOR
Intervention: Intensive chemotherapy alone
Number of subjects: 0
Study 2561145 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirapril 12.5 mg
Number of subjects: 8
Study 2561145 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirapril 25 mg
Number of subjects: 8
Study 2561145 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 5579492 — intervention group
Group type: EXPERIMENTAL
Intervention: Detergents containing proteolytic enzymes
Number of subjects: 4130
Study 5579492 — intervention group
Group type: COMPARATOR
Intervention: Conventional detergents
Number of subjects: 4130
Study 5579492 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme products
Number of subjects: 4130
Study 5579492 — intervention group
Group type: EXPERIMENTAL
Intervention: Clothes washed in enzyme products
Number of subjects: 4130
Study 31238961 — intervention group
Group type: EXPERIMENTAL
Intervention: Giant cell arteritis patients
Number of subjects: 881
Study 31238961 — intervention group
Group type: COMPARATOR
Intervention: Population controls
Number of subjects: 881
Study 28695606 — intervention group
Group type: EXPERIMENTAL
Intervention: Chrysin 50 mg/day
Number of subjects: 20
Study 28695606 — intervention group
Group type: EXPERIMENTAL
Intervention: Chrysin 75 mg/day
Number of subjects: 20
Study 28695606 — intervention group
Group type: COMPARATOR
Intervention: Control (Ch-0)
Number of subjects: 20
Study 26488111 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based treatment (FBT)
Number of subjects: 82
Study 26488111 — intervention group
Group type: COMPARATOR
Intervention: Control group (brief hospitalization for medical stabilization and hospitalization for weight restoration to 90% expected body weight)
Number of subjects: 82
Study 23856657 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment modalities (specific modalities not detailed)
Number of subjects: 161
Study 23856657 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation session content
Number of subjects: 161
Study 23856657 — intervention group
Group type: EXPERIMENTAL
Intervention: Sudden gains
Number of subjects: 161
Study 21873253 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-L polyethylene glycol (PEG)
Number of subjects: 50
Study 21873253 — intervention group
Group type: COMPARATOR
Intervention: magnesium citrate
Number of subjects: 50
Study 19842887 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ventilation during CPB
Number of subjects: 46
Study 19842887 — intervention group
Group type: COMPARATOR
Intervention: Standard nonventilated CPB
Number of subjects: 46
Study 17030532 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day antibiotic therapy (n = 34)
Number of subjects: 69
Study 17030532 — intervention group
Group type: COMPARATOR
Intervention: 14-day antibiotic therapy (n = 35)
Number of subjects: 69
Study 17030532 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day therapy for Staphylococcus aureus infection (n = 7)
Number of subjects: 69
Study 17030532 — intervention group
Group type: COMPARATOR
Intervention: 14-day therapy for Staphylococcus aureus infection (n = 7)
Number of subjects: 69
Study 17030532 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day therapy for non-S. aureus infections
Number of subjects: 69
Study 17030532 — intervention group
Group type: COMPARATOR
Intervention: 14-day therapy for non-S. aureus infections
Number of subjects: 69
Study 14719048 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (2 mg)
Number of subjects: 9
Study 14719048 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 11352132 — intervention group
Group type: EXPERIMENTAL
Intervention: S1 (arrow pointing left or right) with color predictive of S2
Number of subjects: 0
Study 11352132 — intervention group
Group type: COMPARATOR
Intervention: Control trials (third color arrow providing no valid information)
Number of subjects: 0
Study 9595966 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrifonate (0.5 mg/kg, 0.9 mg/kg, or 2.0 mg/kg for 2 weeks followed by maintenance doses of 0.2 mg/kg, 0.3 mg/kg, or 0.65 mg/kg for 10 weeks)
Number of subjects: 480
Study 9595966 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrifonate
Number of subjects: 480
Study 9595966 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 480
Study 1991950 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate (1.2 grams elemental calcium/day)
Number of subjects: 42
Study 1991950 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 6340583 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of gentamicin sulfate and betamethasone phosphate
Number of subjects: 79
Study 6340583 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin sulfate
Number of subjects: 79
Study 6340583 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone phosphate
Number of subjects: 79
Study 6340583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 29385007 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (1.09 g ethanol·kg fat-free body mass)
Number of subjects: 10
Study 29385007 — intervention group
Group type: COMPARATOR
Intervention: No alcohol (placebo; volume of alcohol replaced with water)
Number of subjects: 10
Study 30917336 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction (MBSR)
Number of subjects: 138
Study 30917336 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 138
Study 30917336 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 138
Study 27407018 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin treatment for 6 months
Number of subjects: 28
Study 28336242 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacritinib 400 mg once daily
Number of subjects: 327
Study 28336242 — intervention group
Group type: COMPARATOR
Intervention: Best Available Therapy (BAT)
Number of subjects: 327
Study 28336242 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacritinib
Number of subjects: 327
Study 24077205 — intervention group
Group type: COMPARATOR
Intervention: Pregabalin 50 mg every 8 hours orally (P group)
Number of subjects: 37
Study 24077205 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 25 mg every 8 hours orally and Imipramine 5 mg every 12 hours orally (P-I group)
Number of subjects: 37
Study 24077205 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 25 mg every 8 hours orally and Mirtazapine 7.5 mg every 12 hours orally (P-M group)
Number of subjects: 37
Study 21430242 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 g of NSP plus 22 g of RS/d
Number of subjects: 46
Study 21430242 — intervention group
Group type: COMPARATOR
Intervention: 25 g of NSP
Number of subjects: 46
Study 21430242 — intervention group
Group type: EXPERIMENTAL
Intervention: RS diet
Number of subjects: 46
Study 21430242 — intervention group
Group type: COMPARATOR
Intervention: Entry diet
Number of subjects: 46
Study 19150863 — intervention group
Group type: EXPERIMENTAL
Intervention: Protection Device (PD)
Number of subjects: 563
Study 19150863 — intervention group
Group type: COMPARATOR
Intervention: No Protection Device (nonprotection)
Number of subjects: 563
Study 19150863 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed Cell Stent
Number of subjects: 563
Study 19150863 — intervention group
Group type: EXPERIMENTAL
Intervention: Open Cell Stent
Number of subjects: 563
Study 17955440 — intervention group
Group type: EXPERIMENTAL
Intervention: PnCRM7 vaccine
Number of subjects: 852
Study 17955440 — intervention group
Group type: COMPARATOR
Intervention: Day care‐attending unvaccinated children in PnCRM7 communities
Number of subjects: 852
Study 15065825 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosol cyclosporin (ACsA)
Number of subjects: 22
Study 15065825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 11573049 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia and postoperative epidural morphine (group 2)
Number of subjects: 1021
Study 11573049 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia and postoperative analgesia with parenteral opioids (group 1)
Number of subjects: 1021
Study 10095403 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical ligament repair (group A)
Number of subjects: 109
Study 10095403 — intervention group
Group type: COMPARATOR
Intervention: Non-operative treatment (group B)
Number of subjects: 109
Study 10095403 — intervention group
Group type: COMPARATOR
Intervention: Non-operative treatment (group D)
Number of subjects: 109
Study 10095403 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (group C)
Number of subjects: 109
Study 7845808 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid membrane leads (30 micrograms of dexamethasone)
Number of subjects: 90
Study 7845808 — intervention group
Group type: COMPARATOR
Intervention: Nonsteroid membrane leads
Number of subjects: 90
Study 2690631 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 69
Study 2690631 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 1096903 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen (750 mg daily)
Number of subjects: 100
Study 1096903 — intervention group
Group type: COMPARATOR
Intervention: Indometacin (150 mg daily)
Number of subjects: 100
Study 29304262 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 21
Study 29137679 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramedullary nail
Number of subjects: 0
Study 29137679 — intervention group
Group type: COMPARATOR
Intervention: Distal locking plate
Number of subjects: 0
Study 26209242 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional surgery + PRF (Group 2)
Number of subjects: 20
Study 26209242 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezosurgery + PRF (Group 3)
Number of subjects: 20
Study 26209242 — intervention group
Group type: COMPARATOR
Intervention: Traditional surgery (Group 1)
Number of subjects: 20
Study 26209242 — intervention group
Group type: COMPARATOR
Intervention: Traditional surgery (Group 4)
Number of subjects: 20
Study 26209242 — intervention group
Group type: COMPARATOR
Intervention: Traditional surgery + PRF (Group 2) vs Traditional surgery (Group 1)
Number of subjects: 20
Study 23216707 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Number of subjects: 96
Study 23216707 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 96
Study 23216707 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 96
Study 23216707 — intervention group
Group type: EXPERIMENTAL
Intervention: ABCB1 SNPs (C3435T, G2677T, C1236T)
Number of subjects: 96
Study 21641515 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese medicine (CM) treatment (Glucosidorum Tripterygll Totorum tablets and Yishen Juanbi tablets)
Number of subjects: 170
Study 21641515 — intervention group
Group type: EXPERIMENTAL
Intervention: Western Medicine (WM) treatment (diclofenec, methotrexate and sulfasalazine)
Number of subjects: 170
Study 21641515 — intervention group
Group type: COMPARATOR
Intervention: Western Medicine (WM) treatment
Number of subjects: 170
Study 21641515 — intervention group
Group type: COMPARATOR
Intervention: Traditional Chinese Medicine (TCM) treatment
Number of subjects: 170
Study 18359425 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted antibiotic therapy (TT)
Number of subjects: 740
Study 18359425 — intervention group
Group type: COMPARATOR
Intervention: No targeted therapy (NoTT)
Number of subjects: 740
Study 16509530 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily comprehensive muscle training programme (4-10 minutes daily)
Number of subjects: 11
Study 16509530 — intervention group
Group type: COMPARATOR
Intervention: Control group (12 matched children with PWS)
Number of subjects: 11
Study 14623660 — intervention group
Group type: EXPERIMENTAL
Intervention: Aircast brace
Number of subjects: 14
Study 14623660 — intervention group
Group type: EXPERIMENTAL
Intervention: Bledsoe brace
Number of subjects: 14
Study 14623660 — intervention group
Group type: EXPERIMENTAL
Intervention: Swede-O brace
Number of subjects: 14
Study 14623660 — intervention group
Group type: COMPARATOR
Intervention: No-brace
Number of subjects: 14
Study 11009231 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexiletine (maximum dose of 1,350 mg/d)
Number of subjects: 12
Study 11009231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9112363 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (0.005 mg/kg)
Number of subjects: 30
Study 9112363 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 9112363 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 30
Study 8495257 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyritinol (PY) 600 mg/day for 1 year
Number of subjects: 281
Study 8495257 — intervention group
Group type: COMPARATOR
Intervention: Auranofin (AU) 6 mg/day for 1 year
Number of subjects: 281
Study 3632393 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose prednisone therapy (1.5 mg/kg daily, max 80 mg for six months)
Number of subjects: 33
Study 3632393 — intervention group
Group type: COMPARATOR
Intervention: Natural history controls
Number of subjects: 33
Study 31913207 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated congenital myogenic ptosis
Number of subjects: 31
Study 31913207 — intervention group
Group type: EXPERIMENTAL
Intervention: Aponeurotic ptosis
Number of subjects: 31
Study 31913207 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 31
Study 29048754 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial scratch (n=150)
Number of subjects: 300
Study 29048754 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=150)
Number of subjects: 300
Study 27030352 — intervention group
Group type: EXPERIMENTAL
Intervention: Registered Dietitian Group (RDG)
Number of subjects: 81
Study 27030352 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CON)
Number of subjects: 81
Study 25634801 — intervention group
Group type: EXPERIMENTAL
Intervention: WBRT + sodium nitrite (267 µg/kg/h for 2 hours before each radiation fraction)
Number of subjects: 20
Study 25634801 — intervention group
Group type: COMPARATOR
Intervention: WBRT alone
Number of subjects: 20
Study 23340564 — intervention group
Group type: EXPERIMENTAL
Intervention: HibMenCY x 4
Number of subjects: 0
Study 23340564 — intervention group
Group type: COMPARATOR
Intervention: HibMenCY x 1
Number of subjects: 0
Study 23340564 — intervention group
Group type: COMPARATOR
Intervention: Hib
Number of subjects: 0
Study 21211975 — intervention group
Group type: EXPERIMENTAL
Intervention: De Marco Formula (DMF) combined with conventional therapy (0, 15 ml/kg day i.m. for 10 days, then twice a week until healing or 52 days)
Number of subjects: 47
Study 21211975 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy alone
Number of subjects: 47
Study 18264992 — intervention group
Group type: EXPERIMENTAL
Intervention: Test procedure for treatment effects among compliers
Number of subjects: 0
Study 18264992 — intervention group
Group type: EXPERIMENTAL
Intervention: Sample size calculation formula
Number of subjects: 0
Study 18264992 — intervention group
Group type: EXPERIMENTAL
Intervention: Monte Carlo simulation
Number of subjects: 0
Study 18264992 — intervention group
Group type: EXPERIMENTAL
Intervention: Parameters affecting sample size
Number of subjects: 0
Study 16945139 — intervention group
Group type: EXPERIMENTAL
Intervention: High-tech veteran (trained echocardiologist using full feature echocardiographic platform)
Number of subjects: 20
Study 16945139 — intervention group
Group type: COMPARATOR
Intervention: Low-tech beginner (echocardiographer with limited training using hand-held echocardiography)
Number of subjects: 20
Study 14513439 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 cGy radiation treatment (group A)
Number of subjects: 0
Study 14513439 — intervention group
Group type: COMPARATOR
Intervention: 1,000 cGy radiation treatment (group B)
Number of subjects: 0
Study 10714094 — intervention group
Group type: EXPERIMENTAL
Intervention: ecNOS gene polymorphism (aa, ab, bb genotypes) in AMI patients
Number of subjects: 121
Study 10714094 — intervention group
Group type: EXPERIMENTAL
Intervention: ecNOS gene polymorphism (aa, ab, bb genotypes) in AMI patients below age 51
Number of subjects: 121
Study 10714094 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking status in young AMI patients
Number of subjects: 121
Study 10714094 — intervention group
Group type: COMPARATOR
Intervention: Incidence of hypertension and diabetes mellitus
Number of subjects: 121
Study 9184614 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (5 to 20 mg/day)
Number of subjects: 2606
Study 9184614 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (5 to 20 mg/day)
Number of subjects: 2606
Study 8241668 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc-fortified formula
Number of subjects: 39
Study 8241668 — intervention group
Group type: COMPARATOR
Intervention: Unfortified formula
Number of subjects: 39
Study 3901209 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin
Number of subjects: 0
Study 3901209 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin/clindamycin
Number of subjects: 0
Study 29636089 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX)
Number of subjects: 207
Study 29636089 — intervention group
Group type: COMPARATOR
Intervention: Tripterygium wilfordii Hook F (TwHF)
Number of subjects: 207
Study 29636089 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate + Tripterygium wilfordii Hook F (MTX + TwHF)
Number of subjects: 207
Study 29636089 — intervention group
Group type: EXPERIMENTAL
Intervention: Tripterygium wilfordii Hook F + Methotrexate (MTX + TwHF)
Number of subjects: 207
Study 27884147 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard cardiac rehabilitation programme + four osteopathic treatments (OT) at weeks 4, 5, 8, and 12 after surgery.
Number of subjects: 308
Study 27884147 — intervention group
Group type: COMPARATOR
Intervention: Standard cardiac rehabilitation programme.
Number of subjects: 308
Study 25139208 — intervention group
Group type: EXPERIMENTAL
Intervention: FUTURE I/II criteria
Number of subjects: 0
Study 25139208 — intervention group
Group type: EXPERIMENTAL
Intervention: PATRICIA criteria
Number of subjects: 0
Study 24261985 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-faceted workplace intervention consisting of participatory ergonomics, physical training, and cognitive behavioral training
Number of subjects: 4
Study 24261985 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 4
Study 20550764 — intervention group
Group type: EXPERIMENTAL
Intervention: QuantiFERON®-TB Gold In-Tube test (QFT-GIT)
Number of subjects: 109
Study 20550764 — intervention group
Group type: EXPERIMENTAL
Intervention: QuantiFERON®-TB Gold In-Tube test (QFT-GIT) with a 24-h delay in incubation
Number of subjects: 109
Study 20550764 — intervention group
Group type: EXPERIMENTAL
Intervention: QuantiFERON®-TB Gold In-Tube test (QFT-GIT) during power outages
Number of subjects: 109
Study 18071011 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled ciclesonide 160 microg daily for 3 weeks
Number of subjects: 26